These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 19356733)
1. Comparison of agmatine with moxonidine and rilmenidine in morphine dependence in vitro: role of imidazoline I(1) receptors. Li F; Wu N; Su RB; Liu Y; Lu XQ; Li J Eur J Pharmacol; 2009 Jun; 612(1-3):1-8. PubMed ID: 19356733 [TBL] [Abstract][Full Text] [Related]
2. IRAS, a candidate for I1-imidazoline receptor, mediates inhibitory effect of agmatine on cellular morphine dependence. Wu N; Su RB; Xu B; Lu XQ; Liu Y; Zheng JQ; Piletz JE; Li J; Qin BY Biochem Pharmacol; 2005 Oct; 70(7):1079-87. PubMed ID: 16112088 [TBL] [Abstract][Full Text] [Related]
3. Modulation of agmatine on calcium signal in morphine-dependent CHO cells by activation of IRAS, a candidate for imidazoline I1 receptor. Wu N; Su RB; Liu Y; Lu XQ; Zheng JQ; Cong B; Li J Eur J Pharmacol; 2006 Oct; 548(1-3):21-8. PubMed ID: 16962578 [TBL] [Abstract][Full Text] [Related]
4. Imidazoline receptor antisera-selected/Nischarin regulates the effect of agmatine on the development of morphine dependence. Li F; Wu N; Su R; Chen Y; Lu X; Liu Y; Li J Addict Biol; 2012 Mar; 17(2):392-408. PubMed ID: 21967557 [TBL] [Abstract][Full Text] [Related]
5. Effect of agmatine on DAMGO-induced mu-opioid receptor down-regulation and internalization via activation of IRAS, a candidate for imidazoline I(1) receptor. Gao Y; Li F; Wu N; Su RB; Liu Y; Lu XQ; Liu Y; Li J Eur J Pharmacol; 2008 Dec; 599(1-3):18-23. PubMed ID: 18845140 [TBL] [Abstract][Full Text] [Related]
6. Role of I1 imidazoline receptors in the sympathoinhibition produced by intracisternally administered rilmenidine and moxonidine. Szabo B; Urban R Arzneimittelforschung; 1997 Sep; 47(9):1009-15. PubMed ID: 9342413 [TBL] [Abstract][Full Text] [Related]
7. Involvement of phosphatidylcholine-selective phospholipase C in activation of mitogen-activated protein kinase pathways in imidazoline receptor antisera-selected protein. Li F; Wu N; Su RB; Zheng JQ; Xu B; Lu XQ; Cong B; Li J J Cell Biochem; 2006 Aug; 98(6):1615-28. PubMed ID: 16598778 [TBL] [Abstract][Full Text] [Related]
8. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Prichard BN; Graham BR Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201 [TBL] [Abstract][Full Text] [Related]
9. Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. Chan CK; Head GA J Hypertens; 1996 Jul; 14(7):855-64. PubMed ID: 8818924 [TBL] [Abstract][Full Text] [Related]
10. Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents. Head GA Ann N Y Acad Sci; 1995 Jul; 763():531-40. PubMed ID: 7677371 [TBL] [Abstract][Full Text] [Related]
11. Testing conception of engagement of imidazoline receptors in imidazoline drugs effects on isolated rat heart atria. Radwanska A; Dlugokecka J; Wasilewski R; Kaliszan R J Physiol Pharmacol; 2009 Mar; 60(1):131-42. PubMed ID: 19439815 [TBL] [Abstract][Full Text] [Related]
12. Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine. van Zwieten PA J Hypertens; 1997 Feb; 15(2):117-25. PubMed ID: 9469786 [TBL] [Abstract][Full Text] [Related]
13. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. Chan CK; Sannajust F; Head GA J Pharmacol Exp Ther; 1996 Feb; 276(2):411-20. PubMed ID: 8632304 [TBL] [Abstract][Full Text] [Related]
14. Evidence that some imidazoline derivatives inhibit peripherally the vasopressor sympathetic outflow in pithed rats. Monroy-Ordoñez EB; Villalón CM; Cobos-Puc LE; Márquez-Conde JA; Sánchez-López A; Centurión D Auton Neurosci; 2008 Dec; 143(1-2):40-5. PubMed ID: 18774761 [TBL] [Abstract][Full Text] [Related]
15. Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension. Yu A; Frishman WH J Clin Pharmacol; 1996 Feb; 36(2):98-111. PubMed ID: 8852385 [TBL] [Abstract][Full Text] [Related]
16. Moxonidine and rilmenidine injected into the medial septal area reduces the salivation induced by pilocarpine. Saad WA; de Arruda Camargo LA; Simões S; Saad WA; Guarda RS; Guarda IF Auton Neurosci; 2004 May; 112(1-2):31-6. PubMed ID: 15233928 [TBL] [Abstract][Full Text] [Related]
17. Attenuated renal response to moxonidine and rilmenidine in one kidney-one clip hypertensive rats. Li P; Penner SB; Smyth DD Br J Pharmacol; 1994 May; 112(1):200-6. PubMed ID: 8032642 [TBL] [Abstract][Full Text] [Related]
18. Moxonidine displays a presynaptic alpha-2-adrenoceptor-dependent synergistic sympathoinhibitory action at imidazoline-1 receptors. Schäfer U; Burgdorf C; Engelhardt A; Raasch W; Kurz T; Richardt G Ann N Y Acad Sci; 2003 Dec; 1009():265-9. PubMed ID: 15028597 [TBL] [Abstract][Full Text] [Related]
20. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. Boronat MA; Olmos G; García-Sevilla JA Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]